合并控制权
竞争对手分析
竞争法
优势(遗传学)
欧洲联盟
审查
欧盟委员会
业务
竞赛(生物学)
佣金
法律与经济学
政治学
国际贸易
法学
经济
市场经济
营销
生态学
生物化学
化学
生物
基因
垄断
作者
J.R. Mulder,Wolf Sauter
标识
DOI:10.1093/jaenfo/jnad029
摘要
Abstract The Illumina/Grail and Towercast rulings of July 2022 and March 2023 create new avenues for the control of concentrations below the European Union (EU) and national turnover thresholds. These new avenues concern (i) a referral to the European Commission by a national competition authority (NCA) and (ii) a review under the EU provision on abuse of dominance by an NCA. In both cases, the rationale seems predominantly based on the need to have effective competition law oversight on the so-called killer acquisitions of emerging competitors and undertakings that aim to extend their dominance by acquiring existing (small but) effective or particularly innovative competitors. The obvious drawback of increasing possibilities of the ex-post merger control is that this comes at a cost to legal certainty and the one-stop-shop principle that has characterized the EU merger control so far. Especially the Towercast judgment calls into question the structure, purpose, and merits of merger control in the EU over the past 35 years. Looking forward, much will depend on how the NCAs and the European Commission will use their new-found powers; some reorganization of merger vetting procedures at the national level may be required. However, it appears likely that the system of merger control in the EU will come to focus more sharply on mergers that raise serious competitive concerns and less on providing a system of comprehensive administrative review, based mainly on size. This may also provide opportunities to rationalize the application of public enforcement capacity.
科研通智能强力驱动
Strongly Powered by AbleSci AI